18F-DOPA PETMRI to accelerate 2nd line treatment of brain tumours
Research type
Research Study
Full title
18-F-DOPA PET imaging to distinguish true tumour progression from pseudo-progression in the context of post radiotherapy adolescent brain tumours with suspicious MRI findings.
IRAS ID
234180
Contact name
Francesco Fraioli
Contact email
Sponsor organisation
University College London
Clinicaltrials.gov Identifier
Z6364106/2019/02/52 , Data Protection
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
Why?
The purpose of this study is to investigate the use of positron emission tomography (PET) scanning using a specific amino acid labelled with radioactive Florine 18 (F-DOPA) to differentiate between normal, but damaged brain tissue vs progression of brain tumours (specifically gliomas) following treatment of these tumours. This would be of significant advantage to patients and clinicians as current methods, including other PET and MRI techniques for this assessment are highly limited in providing this information for up to 3-months following treatment.
What?
The study will focus on patients who are post-treatment for glioma brain tumours and will make use of 18F F-DOPA in combination with PET/MRI imaging.
Who?
Both adults and children who have had indeterminate findings using MR imaging post-treatment. This would exclude patients with MRI contra-indications, including electronic implants, allergies to MRI contrast media etc.
Where?
Injection and imaging will be undertaken at the integrated PET/MRI facility in the Macmillan Cancer Centre, London, UK.
How?
Injection of the F-DOPA tracer will allow the PET element of the scanner to localise areas of the brain that are metabolising the labelled amino acid, at the same time the MRI element will be able to obtain high-resolution anatomical and physiological data which can be co-registered with the PET data to produce excellent quality, multi-modal images of the brain. Quantitative analysis as well and visual evaluation will be made of the images with a view to effectively differentiating between recurrence and inflammation of surrounding tissue.REC name
London - Hampstead Research Ethics Committee
REC reference
20/LO/0996
Date of REC Opinion
23 Oct 2020
REC opinion
Further Information Favourable Opinion